ArticleFrontiers in immunology2026
Early monocyte subset signatures predict outcomes in unvaccinated COVID-19 patients.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is characterized by complex immune responses, with monocytes playing a central role in disease pathogenesis. Objective: This study aimed to evaluate the profiles of monocytes and their receptor expression during the first week of hospitalization in unvaccinated patients with COVID-19, stratified by clinical outcome: discharged or deceased. Methods: Peripheral mononuclear cells from hospitalized patients were analyzed by flow cytometry to characterize classical, intermediate, and non-classical monocytes, along with the expression of CD169, CD209, and TLR2, TLR3, TLR4, and TLR9. Result: Patients in whom death was the outcome exhibited a significant reduction in classical monocytes and an expansion of non-classical monocytes early during hospitalization. Additionally, non-classical monocytes from deceased patients showed increased expression of CD169 and greater intensity of CD209 expression. Enhanced expression of TLR2 across all monocyte subsets and increased TLR4 expression specifically in non-classical monocytes were also associated with mortality. Correlation network analysis revealed more complex and dysregulated interactions among monocyte subsets and immune markers in deceased patients compared with discharged individuals. Conclusion: Our findings demonstrate that, during the first week of hospitalization, alterations in monocyte distribution and activation status are strongly associated with COVID-19 severity. Increased expression of CD169, CD209, TLR2, and TLR4, particularly in non-classical monocytes, reflects heightened innate immune activation and may contribute to poorer disease outcomes. Collectively, these results highlight the potential of monocyte subsets and their associated receptors as early prognostic biomarkers and provide insight into the immunopathogenesis of severe COVID-19.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.